Please use this identifier to cite or link to this item:
|Title:||Review article: hypoxia and hepatic drug metabolism--clinical implications.||Austin Authors:||Angus, Peter W ;Morgan, Denis J;Smallwood, R A||Affiliation:||Department of Medicine, University of Melbourne, Austin Hospital, Heidelberg, Victoria, Australia||Issue Date:||1-Jun-1990||Publication information:||Alimentary Pharmacology & Therapeutics; 4(3): 213-25||Abstract:||Most major pathways of hepatic drug metabolism are dependent on oxygen. Hepatic mixed-function oxidases use oxygen directly as a substrate, while many other enzyme systems are indirectly dependent on oxygen for the generation of essential co-factors, such as NAD+ and ATP. Studies in vitro show that many of these oxygen-dependent reactions are impaired by relatively minor reductions in oxygen supply, of a magnitude likely to be encountered in vivo. Phase I metabolism by mixed-function oxidases appears to be more sensitive to hypoxia than phase II drug conjugation, although the oxygen requirements of conjugation reactions, such as glucuronidation, may be greatly enhanced by poor nutrition or fasting. Studies in humans are few, but in general they affirm the potential importance of the effects of hypoxaemic states on hepatic drug elimination. On present evidence, special care should be taken in hypoxic patients with drugs extensively metabolized by the liver, particularly those which have a low therapeutic ratio.||Gov't Doc #:||2104086||URI:||http://ahro.austin.org.au/austinjspui/handle/1/11147||URL:||https://pubmed.ncbi.nlm.nih.gov/2104086||Type:||Journal Article||Subjects:||Animals
|Appears in Collections:||Journal articles|
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.